Navigation Links
Compendia Bioscience Announces the Release of Oncomine 4 Research Edition
Date:9/23/2009

ANN ARBOR, Mich., Sept. 23 /PRNewswire-USNewswire/ -- Compendia Bioscience, Inc. today announced the release of Oncomine Research Edition version 4.2, a significant product upgrade for the academic and non-profit communities. Since its inception, Compendia has been fully committed to supporting academic and non-profit cancer research efforts worldwide. This new version of Oncomine features a completely redesigned user-interface, improved search and filter capabilities, and several other new features designed to make gene discovery and validation simpler and more efficient.

Cancer researchers have made Oncomine the industry standard with over 12,000 academic users. These researchers use Oncomine to discover new genes, evaluate pathways and better understand specific cancer types resulting in the publication of more than 200 peer reviewed journal articles. Oncomine has led to several major cancer research discoveries such as the recent publication of AGTR1 overexpression and sensitivity to losartan in breast cancer (Proc Natl Acad Sci U S A. 2009 Jun 1).

"We are really pleased to release this exciting new version of Oncomine to the academic research community," said Compendia's Co-Founder and CEO Dan Rhodes, Ph.D. "We are confident that Oncomine 4 will continue to accelerate cancer research and lead to important new discoveries."

New Features and Capabilities in Oncomine 4 Research Edition

  • Unified interface, optimizing workflows with rapid navigation and visualization of results through three interactive panes
  • Smart search and browse, giving users the ability to search multiple terms within a single instance
  • The Compendia Ontology, standardizing a set of rules used to characterize Oncomine data, which drives consistent downstream analyses
  • Standardized analyses, comparing gene expression profiles between normal and cancer samples
  • Meta COPA, adding this analysis to the Oncomine interface for quick results
  • Concepts Map integration, allowing smooth workflows

While improved user experience was the driving force in Oncomine 4 Research Edition, the entire Oncomine database was scrutinized in an effort to standardize and catalog all data points. In creating the Compendia Ontology, 300,000+ sample facts across 30,000+ samples were individually reviewed and terms normalized.

About Compendia Bioscience, Inc.

Compendia Bioscience is dedicated to harnessing the global collection of high throughput molecular data to provide researchers with the data and analysis tools necessary to validate biomarker and gene target discoveries, better understand mechanisms of disease, and optimize clinical outcomes. www.compendiabio.com

About Oncomine(TM)

Oncomine combines a rapidly growing compendium of 39,000+ expertly curated cancer genomic profiles with a sophisticated analysis engine and a powerful web application for data mining and visualization. Oncomine facilitates target discovery and validation and supports the prioritization of tumor populations for drug development. http://www.compendiabio.com/products/products.htm


'/>"/>
SOURCE Compendia Bioscience, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Compendia Bioscience Announces the Receipt of a $2.4M SBIR Award and Related Management Changes
2. Compendia Bioscience Announces the Release and Availability of Oncomine(TM) Research Premium Edition
3. GlaxoSmithKline Signs Licensing Agreement With Compendia Bioscience
4. On Third Anniversary, Compendia Bioscience Announces Continued Revenue Growth, Major Long-Term Customer Contracts and Forecasts Profitability
5. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
6. Selection of Development Candidate Triggers $0.5 Million Milestone Payment to Ardea Biosciences, Inc.
7. ImmuneRegen BioSciences Files 8-K that Highlights Enclosed Shareholder Letter Discussing Recent Achievements and Outlook
8. Ohio Ranks Best in the Midwest for Venture Capital Investment in Health Care Bioscience Industry
9. ONCOSCIENCE AG, THE EUROPEAN PARTNER OF YM BIOSCIENCES, ANNOUNCES COMPLETION OF PATIENT ENROLLMENT IN PHASE III BRAIN CANCER TRIAL OF NIMOTUZUMAB
10. Pressure BioSciences, Inc. Reports Second Quarter 2007 Financial Results and Provides Business Update
11. YM BIOSCIENCES, EUROPEAN PARTNER, ONCOSCIENCE AG, ANNOUNCES INITIATION OF ADVANCED NIMOTUZUMAB TRIALS IN ADULT GLIOMA AND PANCREATIC CANCER
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... CLEVELAND , June 27, 2016  Global ... average 4.6 percent through 2020 to $7.2 billion.  ... (food and beverages, cleaning products, biofuel production, animal ... and biotechnology, diagnostics, and biocatalysts). Food and beverages ... gains driven by increasing consumption of products containing ...
(Date:6/27/2016)... ... June 27, 2016 , ... Parallel 6 , the leading software as ... Clinical Reach Virtual Patient Encounter CONSULT module which enables both audio and video ... trial team. , Using the CONSULT module, patients and physicians can schedule a face ...
(Date:6/27/2016)... --  Ginkgo Bioworks , a leading organism design ... awarded as one of the World Economic Forum,s ... innovative companies. Ginkgo Bioworks is engineering biology to ... in the nutrition, health and consumer goods sectors. ... including Fortune 500 companies to design microbes for ...
(Date:6/24/2016)... ... June 24, 2016 , ... Researchers at the Universita Politecnica delle Marche in ... peritoneal or pleural mesothelioma. Their findings are the subject of a new article on ... biomarkers are signposts in the blood, lung fluid or tissue of mesothelioma patients that ...
Breaking Biology Technology:
(Date:4/28/2016)... SAN FRANCISCO and BANGALORE, India ... part of EdgeVerve Systems, a product subsidiary of Infosys (NYSE: ... service provider, today announced a global partnership that ... convenient way to use mobile banking and payment services. ... Mobility is a key innovation area for financial services, but ...
(Date:4/19/2016)... April 20, 2016 The new ... a compact web-based "all-in-one" system solution for all door ... reader or the door interface with integration authorization management ... control systems. The minimal dimensions of the access control ... the building installations offer considerable freedom of design with ...
(Date:4/13/2016)... physicians supporting Medicaid patients in Central Florida ... telehealth thanks to a new partnership with higi.   ... can routinely track key health measurements, such as blood ... they opt in, share them with IMPOWER clinicians through ... location at no cost. By leveraging this data, IMPOWER ...
Breaking Biology News(10 mins):